Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial

Table 4

The mRS score distribution.

	No. (%)			value
	Experimental group ()	Control group ()	Total ()
Baseline
0-no symptoms at all	0 (0%)	1 (1.1%)	1 (0.6%)	0.028
1-no significant disability despite symptoms	0 (0%)	5 (5.6%)	5 (2.8%)
2-slight disability	8 (8.9%)	12 (13.3%)	20 (11.1%)
3-moderate disability	31 (34.4%)	38 (42.2%)	69 (38.3%)
4-moderately severe disability	51 (56.7%)	34 (37.8%)	85 (47.2%)
5-severe disability	0 (0%)	0 (0%)	0 (0%)
6-dead	0 (0%)	0 (0%)	0 (0%)
Hospital discharge
0-no symptoms at all	10 (11.1%)	9 (10%)	19 (10.6%)	0.085
1-no significant disability despite symptoms	43 (47.8%)	30 (33.3%)	73 (40.6%)
2-slight disability	21 (23.3%)	21 (23.3%)	42 (23.3%)
3-moderate disability	10 (11.1%)	11 (12.2%)	21 (11.7%)
4-moderately severe disability	6 (6.7%)	17 (18.9%)	23 (12.8%)
5-severe disability	0 (0%)	0 (0%)	0 (0%)
6-dead	0 (0%)	2 (2.2%)	2 (1%)
Day 30
0-no symptoms at all	25 (27.8%)	25 (27.8%)	50 (27.8%)	0.302
1-no significant disability despite symptoms	53 (58.9%)	47 (52.2%)	100 (55.6%)
2-slight disability	6 (6.7%)	6 (6.7%)	12 (6.7%)
3-moderate disability	1 (1.1%)	6 (6.7%)	7 (3.9%)
4-moderately severe disability	5 (5.6%)	4 (4.4%)	9 (5.0%)
5-severe disability	0 (0%)	0 (0%)	0 (0%)
6-dead	0 (0%)	2 (2.2%)	2 (1%)

Abbreviations: mRS: modified Rankin Scale.